Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience
ConclusionImmune checkpoint inhibition was relatively well tolerated in a cohort of pediatric patients spanning several CNS tumor diagnoses. Results from prospective clinical trials will be critical to inform clinical decisions.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Tumor | Cancer & Oncology | Children | Clinical Trials | Craniopharyngioma | Diabetes | Diabetes Type 1 | Endocrinology | Ependymoma | Germ Cell Tumors | Glioma | Hypothyroidism | Immunotherapy | Neurology | Pediatrics | Radiation Therapy | Skin | Toxicology | Yervoy